Bladder Cancer Drug Pipeline Update 2008

According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 year survival rate is 94%.

There are today no less than 58 therapeutics targeting bladder cancer, from early preclinical to marketed drugs. Bladder Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 39 different targets. These targets are further categorized on the CD-ROM by 21 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Bladder Cancer Drug Pipeline Update is organized.

How May Drug Pipeline Update Be of Use?

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

* Find competitors, collaborations partners, M&A candidates etc.

* Jump start competitive drug intelligence operations

* Excellent starting point for world wide benchmarking

* Compare portfolio and therapy focus with your peers

* Speed up pro-active in-/out licensing strategy work

* Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.

Drug Pipeline Update is delivered to you as a CD-ROM application, which requires no installation on your computer. Please read more about application features and system requirements - hit more..

May 2008
More...
Price: $1,550.00 / GBP775.00